Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NEPOVppHfW6ldHnvckBCe3OjeR?= M1rs[VIh|ryP NXnyW4lZOSCq MVXpcohq[mm2czD0bIUhVC2GT2DBJEgzOMLizszNLU1qdmS3Y3XkJJRz[W6|aXXueEBGWktzL{KgdIhwe3Cqb4L5cIF1cW:wwrC= MVWyOlM3OzF7MR?=
C2C12 MVjGeY5kfGmxbjDBd5NigQ>? M4PkR|HDqM7:Zz;tcC=> M2nlWVHDqGh? M3PVb4Fjd2yrc3jld{BkgXSxa3nu[UBz\WynYYPlJIZzd21iQ{LDNVIhdXmxdIXi[ZM> Mm\BNlYzQTF{N{m=
MEFs WT MUnGeY5kfGmxbjDBd5NigQ>? NWC1cY5yPcLizszN MlqxNlAhdWmw NUD5fJFR[2G3c3XzJJJme2mmZX70JIVvgnmvZYOgd5VkcCCjczDORWdVNUeIUDygeI8h\GmoZoXz[UBj[WOtIITvJJRp\SCHUh?= MlXvNlYyQTZyMkO=
MEFs VAMP7 KO MXrGeY5kfGmxbjDBd5NigQ>? MmT0OeKh|ryP NH7qbYwzOCCvaX6= MV\jZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT NGfBe4QzPjF7NkCyNy=>
SMCs MoHMSpVv[3Srb36gRZN{[Xl? MUixNOKhyrWpL33s NGrUXIgxNTF{IHi= NUnCRlc3TE2VTx?= NGnXUIx{cG:5czDhJJRz\W6mIITve4Fz\HNiYTDobYdp\XJiY3;uZ4VvfHKjdHnvckBw\iC2aHWgSXIwW1JibnX0e49zcyCrbjD0bIUheGW{aX71Z4xm[XJiYYLlZeKh M{jyVVI3OTd{MEiw
SMCs MmjxSpVv[3Srb36gRZN{[Xl? MUexNOKhyrWpL33s MoHMNE0yOiCq NWPxTZg5TE2VTx?= MkDxZ4F2e2W|IHGgeJJidnOrZX70JGNiOiwEoILlcIVie2ViZoLvcUB1cGViRWKvV3LDqA>? NXv2WZFOOjZzN{KwPFA>
HEMC-1 MnLISpVv[3Srb36gRZN{[Xl? NXfmUoNXOC5zwrFCuYcwdWx? NYDMOJVPOjUEoHi= M3:yOoNifXOnczDhJIhq\2incjDpcohq[mm2b4L5JIVn\mWldDDvckBmgG:leYTvd4l{KHSqYX6gco9kd2Sjen;s[S=> M2\u[|I2QTd{N{W5
HUVEC NFzUSI5HfW6ldHnvckBCe3OjeR?= M{facFExyqEQvF2= M2C5SlHDqGh? MWjEUXNQ MV7hZo9tcXOqZYOgbJlxd3irYT3pcoR2[2WmIILlcIVie2Vib3[gRXRRKG[{b32gZZBq[2GuIHHu[EBj[XOxbHH0[ZJidCC|dYLmZYNmew>? M2PtPVI2QTV4OUi4
HUVEC NI\UVIhHfW6ldHnvckBCe3OjeR?= MUCxNOKh|ryP MmnyNeKhcA>? MkXkSG1UVw>? M37nZ4lv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= M{HqVlI2QTV4OUi4
Caco-2 NILy[4tHfW6ldHnvckBCe3OjeR?= M4LHUFIvPSEQvF2= MVezNEBucW5? MUTheJRmdnWjdHXzJJRp\SCWR1[t{tIyNW2nZHnheIVlKGmwY4LlZZNmKGmwIGPFVnQh\nWwY4Tpc44> MVKyOVk2PDl|MR?=
NRK MVrGeY5kfGmxbjDBd5NigQ>? NGnPVYMzODEkgJXu[{9udA>? NHLLW3U16oDHaB?= MX\EUXNQ NGTtfWFz\XOldXXzJI1qfG:2aXOgdJJw\3Knc4Ppc44> MV6yOVk1QDV6Nh?=
HeLa NHvX[4VHfW6ldHnvckBCe3OjeR?= NGHyVGczODEkgJXu[{9udA>? M3nHcFMhcA>? Mn\NSG1UVw>? M1PLeYlv\HWlZYOgeIhmKGG{dHnmbYNq[WxiYoLlZYsufXBib3[geIhmKEexbHfpJINwdXCuZYi= M2jXcVI2QTR6NUi2
COS MV\GeY5kfGmxbjDBd5NigQ>? Mn34NUDPxGdxbXy= NI\TfHM{KGh? NEG2eINkd22ybHX0[Yx6KGSrc4DldpNmeyC2aHWgRXAuOSC|aXfuZYzDqA>? MUCyOVkyPTlyMB?=
DF1  NYTzdXhxTnWwY4Tpc44hSXO|YYm= MoPwNeKh|ryPwrC= MUC0PEBp NEXqW2ZFVVOR MW\kbZNx\XK|ZYRCpJRp\SCneH;n[Y5wfXNiQ2PHZYxPSWOWMjDwdo91\Wmw NVLYPY1XOjV6MEewOVQ>
nHDFs  MlXLSpVv[3Srb36gRZN{[Xl? MlLlNeKh|ryPwrC= MXiyxsBp NVz1WppQeHKndnXueJMhfGinIHHzd4Vu[my7IH;mJIN6fG:|b3zpZ{Bkd2G2IIDyc5RmcW6|IH;ueI8hT2:uZ3mgcYVu[nKjbnXz M2HBXVI2Pzd{NkG2
FRT  Mn3kSpVv[3Srb36gRZN{[Xl? Ml3POUDPxGdxbXy= NYrTSHZSOsLiaB?= M4ftbYJtd2OtczD0doFn\mmla3nu[{B1cHKxdXfoJJRp\SCJb3znbUBkd22ybHX4JIJ6KGmwaHnibZRqdmdiRWKteI8uT2:uZ3mgeJJidnOyb4L0 NVrtNYtPOjV5NkexNVU>
FRT  MWPGeY5kfGmxbjDBd5NigQ>? MmHQOUDPxGdxbXy= NYPJXXZZOsLiaB?= MlrmdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm MU[yOVc3PzFzNR?=
HepG2  NI\xb|FHfW6ldHnvckBCe3OjeR?= MmLjNgKBkcL3TdMg MWmyOEBp MmPBSG1UVw>? M13HfYRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiUGjSJI1TVkF? MVmyOVYyPjV7Nx?=
SMCs M{HPdGZ2dmO2aX;uJGF{e2G7 NGjocGYy|rypL33M NYDmWFE1OyCq MVLhZ4N2dXWuYYTld{BEVlC\MjDwdo91\WmwIHnuJJRp\SCHUjDjc41x[XK2bXXueEBidmRibn:gcI9v\2W{IHPvMYxw[2GuaYrl[EB4cXSqIITo[UBId2ypaTDtZZJs\XMEoB?= M2DTXlI2PTh7NEK1
OB-6 M3jLXGFxd3C2b4Ppd{BCe3OjeR?= NHzjO|UzNjgEoN88US=> NYL0NpdbPDhiaB?= MX7pcoR2[2W|IHHwc5B1d3Orcx?= NWniSWc2OjV3M{K0PFA>
iPSC-CMs  NXnjVVAxTnWwY4Tpc44hSXO|YYm= MojqOVAxKG6pL33s NXTYbXVvPDhiaB?= M4e1PIlv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJJRp\SCqaXfo[ZIhdW:kaXzpeJkhVEGPUIOgZZQhfGinIHPvd5Qhd2ZidHjlJIxwf2W{IH3vZoltcXS7IIPw[YNq\XN? MmG2NlU1QDh4Nk[=
SP-Nluc NVn2TIJ2TnWwY4Tpc44hSXO|YYm= NHzNSoc2KG2pL33M M4nxWFYhcA>? NGf3VmVFVVORwrC= MljGZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> NX3lUFcxOjV|OUK5PVg>
PEXEL-Nluc M1PofmZ2dmO2aX;uJGF{e2G7 MU[1JI1oN22O MlXOOkBp M1HJUWROW00EoB?= MlzrZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> NVfBdJFQOjV|OUK5PVg>
H1299 NVL1TYtrTnWwY4Tpc44hSXO|YYm= NGHGWmUyOCEQvHevcYw> NF31dHIzPCCq MYXpcoR2[2W|IHH1eI9xcGGpedMg M{DqT|I2Ozh6OUew
MDA-MB-231 NGnPbWxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml3PNQKBmzVyIN88[{9uVA>? MXm0PEBp NFfOVZVGSzVywrC9JFAvODF4INM1[{9uVA>? NXj4Z3JROjV|NU[1Olc>
MDA-MB-231 NXTmdng4SXCxcITvd4l{KEG|c3H5 NH7uTHQxNjFizsznM41N NI\VZpg1KGh? NVTLeJRYcW6mdXPld{BieG:ydH;zbZM> NWLncmk3OjV|NU[1Olc>
MDA-MB-231 NF7WcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjTbpQxNjBzL{CuNFUh|rypL33M NFTwNHczPCCq NVm0bFRlcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kB{fWJvR{GgZ4VtdCCmZXLybZM> Mle2NlU{PTZ3Nke=
MDA-MB-231 NI\3UHVCeG:ydH;zbZMhSXO|YYm= MoPwNE4xPeLCk{Gg{txoN22O M3jXSlI1KGh? NUT2c|VUcW6mdXPld{BRSVKSIDjwc4x6KEGGUD3ybYJwe2VicH;sfY1memG|ZT2xLUBkdGWjdnHn[S=> MX:yOVM2PjV4Nx?=
MDA-MB-231 M{[5PGZ2dmO2aX;uJGF{e2G7 MVyw5qCUPTBizsznM41N MXWyOEBp M2Ll[IlvcGmkaYTzJJRp\SCob4LtZZRqd25ib3[gN2Qh[W6mIELEJINwdG:waXXz MWWyOVM2PjV4Nx?=
A172 NEPEPItHfW6ldHnvckBCe3OjeR?= NVviOXYyOTEEoN88[{9udA>? NXvNdY9yPMLiaB?= MVTEUXNQyqB? M4TId5Jme3WudIOgbY4hfGinIILleJJw\3KjZHWgeJJidnOyb4L0JI9nKG[udX;y[ZNk\W62IHfyZY52dGW| NXvNRnpyOjV{M{m1NFc>
KMS-6 MWLGeY5kfGmxbjDBd5NigQ>? MlzMNeKh|ryPwrC= M4PMSlI1KGh? M2PxUoV5cGmkaYTzJIhidGZidHjlJJNm[3KndHnvckBw\iCpYXzhcolvNUyLIHHzJIRq\CC2aHWgZ49vfHKxbB?= Ml34NlUzOjlzMk[=
MEC M1X3Z2Z2dmO2aX;uJGF{e2G7 MnvUNUDPxE1? M4HE[VEvPSCq MY\jZZV{\XNiYTDkdoFu[XSrYzDk[YNz\WG|ZTDpckB1cGVic4Xy[oFk\SCYRVfGVlI> MYCyOVIzQDhzNR?=
HEK293/hERG NHv6TJlHfW6ldHnvckBCe3OjeR?= NX36N2VJOTEEoN88US=> NXj0c2pGOcLiaB?= M3[5WJJme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi NVLicVIxOjV{MUi0Olk>
RBE4 NHP4OIJCeG:ydH;zbZMhSXO|YYm= M3jGUVLDqM7:TR?= MYGz5qCUOjUEoHi= M1XYT4lv\HWlZYOgZZBweHSxc3nzJJRqdWViZHXw[Y5l\W62bIm= NITLRoozPTF{OECyOS=>
RBE4 NGXNe2tHfW6ldHnvckBCe3OjeR?= MkD4NuKh|ryP MVqz5qCUOjUEoHi= NIPxcm1qdmO{ZXHz[ZMhfGinIGjCVFEheHKxdHXpckBt\X[nbIOgZYZ1\XJiMzDhcoQhPsLiaDDv[kB1emWjdH3lcpQ> MmDXNlUyOjhyMkW=
RBE4 NU\h[VE5TnWwY4Tpc44hSXO|YYm= Mny1NuKh|ryP M1XEbFPjiJN{NNMgbC=> NFzqW5lqdmO{ZXHz[ZMh[WO2aY\lJINie3Cjc3WtNVIhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? M3\rbVI2OTJ6MEK1
RBE4 MnHSSpVv[3Srb36gRZN{[Xl? M4XZRVLDqM7:TR?= MWGz5qCUOjUEoHi= MnfZbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUl;TJJRqdWVvZHXw[Y5l\W62bIm= NF7MW4czPTF{OECyOS=>
RBE4 MXrGeY5kfGmxbjDBd5NigQ>? NGjW[nozyqEQvF2= MmfiN-KBmzJ2wrDo NYS3ZlZGcW6mdXPld{BiKGSnbHH5[YQh\GWybHX0bY9vKG:oIITo[UBGWiCFYUKrxsBkd262ZX70JIF1KDcEoHigc4YhcW6ldXLheIlwdiC|aXfubYZq[2GwdHz5 MX2yOVEzQDB{NR?=
RBE4 MoHPSpVv[3Srb36gRZN{[Xl? Mo\rNuKh|ryP NEW0fY0{6oDVMkVCpIg> MnjWbY5lfWOnczDhckBwfmW{bH;h[EBw\iCFYUKrxsBqdiC2aHWgcYl1d2Oqb37kdoliKGmwIITo[UBncXK|dDC2xsBpKG:oIHnuZ5Vj[XSrb36gLJDjiIl:4pEJNE4xODFrIHL1eEBE[TJtwrDs[ZZmdHNiaX6geIhqeyCxcnfhcoVtdGViZHXjdoVie2WmIHHmeIVzKDF{wrDoJI9nKGmwY4XiZZRqd25? M2K2UVI2OTJ6MEK1
Huh-7  M1XHXmZ2dmO2aX;uJGF{e2G7 NXv4cphjOc7:Zz;tUC=> NFrUR|I{6oDVMkVCpIg> NFjEXIdqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NGf2T|EzPTB{NkG3OC=>
HepG2  M321Z2Z2dmO2aX;uJGF{e2G7 NEH4N2gy|rypL33M MlrEN-KBmzJ2wrDo MXHpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M3LnUlI2ODJ4MUe0
H838-LKB1 MkeySpVv[3Srb36gRZN{[Xl? M{LiS|MxyqCwZz;tcC=> NXy0RnA3OTJxMUigbC=> NXzselc1cW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? M1\LWlI2ODFzMEiy
H838-KDLKB1  MUfGeY5kfGmxbjDBd5NigQ>? M4fGZlMxyqCwZz;tcC=> NEL0RXQyOi9zODDo M{i3OIlv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiQnnQxsA> M3;6TlI2ODFzMEiy
H838-KDLKB1  MUHGeY5kfGmxbjDBd5NigQ>? NV3GTY9UOzEEoH7nM41t MX2xNk8yQCCq M1XSU4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIDoc5NxcG:{eXzheIVlKGWLRkNOtUApeGixc4Doc{1mUUZ{zsGp Mmj3NlUxOTFyOEK=
3T3-L1 NH3uOZNHfW6ldHnvckBCe3OjeR?= NVzQNnpqPSEQvHevcYw> Mn;2N|AhdWmw NVXYc2JodWmvaXPzJJRp\SCnZn\lZ5R{KG:oIHnud5VtcW5iYX7kJINifXOnczDyc4J2e3RicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEApW2W{IES3N{kh[W6mIIDoc5NxcG:{eXzheIlwdiCxZjDBV|E3OCBqVHjyJFY1OiCjbnSgV4VzKDV6ODm= NGHTUGQzPDh2M{iyOy=>
3T3-L1 Mlj2SpVv[3Srb36gRZN{[Xl? NUjhVlFvPSEQvHevcYw> NYLMW25EOzBibXnu MWXy[YNieGm2dXzheIV{KGmwc4XsbY4h[WO2aX;uJJdqfGhicnXzdIVkfCC2bzDy[Yd2dGG2aX7nJGFsfCCjY4Tpeol1gSCjbnSgRXMyPjBicHjvd5Bpd3K7bHH0bY9v MlLCNlQ5PDN6Mke=
3T3-L1 Mn\pSpVv[3Srb36gRZN{[Xl? NVj2S491PSEQvHevcYw> M4q3eVMxKG2rbh?= MUXjZZV{\XNicnX2[ZJ{cWKuZTDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPA>? MonyNlQ5PDN6Mke=
3T3-L1 M{PQNWZ2dmO2aX;uJGF{e2G7 NVvyd2xnPSEQvHevcYw> MV:xxsBp M3jHZYNifXOnczDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPCCkdYSgco91KGmwY4LlZZNmKGmwIHfseYNwe2VidYD0ZYtm NVjPZXl[OjR6NEO4Nlc>
3T3-L1 NVzQbpRGTnWwY4Tpc44hSXO|YYm= NGf0WJA2KM7:Zz;tcC=> NXnEVG55OcLiaB?= NEHy[mlk[XW|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5Rweg>? NY[0fIZKOjR6NEO4Nlc>
HeLa  Ml;wSpVv[3Srb36gRZN{[Xl? M2K2fVUh|rypL33s M2nNWFMhcA>? NETUXINk[XW|ZYOgcpVkdGWjcjDlfINtfXOrb36gc4YhfGinIF\vfG8yKHS{YX7zZ5JqeHSrb36g[oFkfG:{IHHu[EBl\WO{ZXHz[ZMhfHKjboPjdolxfGmxbjDv[kBHd3iRMT3y[Yd2dGG2ZXSg[4Vv\XN? NXLZfYxVOjR6NEO4Nlc>
HEK293 MmDFSpVv[3Srb36gRZN{[Xl? M17sbFXDqM7:Zz;tcC=> NFXZSpIyOsLiaB?= MmPiZYJwdGm|aHXzJGNOSS2rbnT1Z4VlKEOURVzENkB{\WO{ZYTpc44> MYeyOFY5PzR|MR?=
COS-1 NXzhfo8{TnWwY4Tpc44hSXO|YYm= MlKwOUDDvWdxbXy= NHLEem4zPCCqwrC= MUXy[ZN1emmldIOgcI9k[WyrenH0bY9vKG:oIF7CJIlvKHSqZTDw[ZJqdnWlbHXhdkBz\Werb39CpC=> NV[3b3JuOjR4N{G3OVE>
PRP M1z0WWZ2dmO2aX;uJGF{e2G7 MmX1NVAh|ryP NH7tdXNi[nKxZ3H0[ZMhW0SILUJOtU1u\WSrYYTl[EBEYEOUNzDlfJRmem6jbHn6ZZRqd28EoB?= NXzqXHJYOjR4Nki3OVA>
RAW264.7 M{DCeWFxd3C2b4Ppd{BCe3OjeR?= MWK0JO69VQ>? NH7QTVc1QCCq MnjqZZR1\W63YYTld{B1cGViaX7obYJqfGmxbjDv[kBwgC2ORFytbY5lfWOnZDDhdI9xfG:|aYOgZY5lKHSqZTDmZYNqdGm2YYTpc44hd2ZiY3jvcIV{fGW{b3yg[YZndHW6IHL5JGFkNWiHLUG4RU1PUDJ? MkP3NlQ3OzlyM{K=
MDMs NGfndWJCeG:ydH;zbZMhSXO|YYm= MXKxNQKBkc7:Zz;tcC=> M1n2bVEzNzF3IHi= NGfNW2hqdmS3Y3XzJIFxd3C2b4Ppdy=> NF3nbpkzPDV3Nk[5OS=>
PMHs  M3fXZ2Z2dmO2aX;uJGF{e2G7 MkDkNVDjiJN{MPMAje69\y:vbB?= NYe2OW5jOjUkgJno NIf6dVJFVVOR MoHFbY5lfWOnZDDFVkB{fHKnc4O= NFTzVHMzPDRyN{K0Ni=>
PMHs  M3r0PWFxd3C2b4Ppd{BCe3OjeR?= MlzpNVDjiJN{MPMAje69\y:vbB?= MVWyOQKBkWh? MVPEUXNQ M122OYlv[3KnYYPld{Bk\WyuIHTlZZRp MXKyOFQxPzJ2Mh?=
HEK293/tau Mn3xSpVv[3Srb36gRZN{[Xl? MnGzOUDPxE1? NGrWRpMyNzJxNDDo NFTGbZFqdmS3Y3XzJGdwdGerIH\yZYdu\W62YYTpc47DqA>? M3H1O|I1OzZ6MEi5
HEK293/tau NWPDemE6TnWwY4Tpc44hSXO|YYm= M{jLUVUh|ryP MnW5N{Bp NW\2ZVVQcW6mdXPld{B1[XViaInw[ZJxcG:|cHjvdplt[XSrb36= NWHBOVZyOjR|NkiwPFk>
ADF MWfGeY5kfGmxbjDBd5NigQ>? NGj6b24yOCEQvF2= NXjuNIdoOTZiaB?= M1TsO4lvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV MlPhNlQzOjh{M{K=
U373  NUD4S3lMTnWwY4Tpc44hSXO|YYm= M4W4WlExKM7:TR?= MlPmNVYhcA>? Mm\MbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> MUOyOFIzQDJ|Mh?=
RKO-HIPK2i MlXtSpVv[3Srb36gRZN{[Xl? MkDGNVAh|ryP MkXuNVYhcA>? MlvibY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NF;4ZmwzPDJ{OEKzNi=>
ADF  M4e1fWZ2dmO2aX;uJGF{e2G7 MVKxNEDPxE4EoB?= NGDj[pM3KGh? MkjVbY1x[Wm{czD0bIUhTENiYXP0bZZifGmxbh?= NVvDdYNlOjR{MkiyN|I>
Huh7 NEW2RpFHfW6ldHnvckBCe3OjeR?= NHrQU|Y2KM7:Zz;tcC=> NUWzWlRXPCCq MmD5ZYJwdGm|aHXzJJRp\SC|ZXPy[ZRqd25ib3[gJIlvfHKjY3XscJVt[XJiQYDvRi=> NVLPfYY6OjRzMECxOFA>
Huh7 MYnGeY5kfGmxbjDBd5NigQ>? M3jxTVUh|rypL33s MojSNUBp MYDjZZV{\XNiYTDzbYdvcW[rY3HueEBqdmO{ZXHz[UBqdiCDcH;CMYNz\XOlZX70dy=> M1m4cVI1OTByMUSw
Huh7 Ml3ySpVv[3Srb36gRZN{[Xl? NGHEbpc26oDVMUFCpI5oN22u NUHPO4FXOTJiaB?= MnWxbY5kemWjc3XzJGFxd0JvY4Lld4NmdnS|IIfpeIhwfXRiaX7obYJqfGmwZzDz[YNz\XSrb36= MmT1NlQyODBzNEC=
BAECs MknISpVv[3Srb36gRZN{[Xl? MX21JO69\y:vbB?= M3n4VVAuPCCq MUTpcoR2[2W|IITo[UBz[XCrZDDk[ZBpd3OyaH;yfYxifGmxbjDv[kBmVk:VIHH0JHNmejFzN{m= NH\HXmYzPDB6NUKyOS=>
Macrophages NXvSOYRlTnWwY4Tpc44hSXO|YYm= M4XwN|cyKML3TR?= MnLBOkBp MYfpcohq[mm2czDseY5ie2mwIHnueIVzdmGuaYrheIlwdsLi MWKyOFA{QTd2MB?=
Colo 205 MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PHfFAuPSEQvHevcWw> NXiyZ21uPDhiaB?= NGTUb2ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDzeZNx\W6|aX;uJIN2dHS3cnXzJJdqfGhiYX6g[ZN1cW2jdHXkJGlEPTBib3[gglE2KG6pL33M MUeyN|k4Ozl7Nh?=
Colo 205 NF7WT4hHfW6ldHnvckBCe3OjeR?= M3GyNVAvODF{LUCuNFI2KM7:Zz;tUC=> NGr5VVQyPCCm M3zGdpJm\HWlZYOgeIhmKGOub37v[4VvcWOrdImgc4YhS2:ubzCyNFUhS1OFcx?= M33PRlI{QTd|OUm2
Colo 205 M4T2SGFxd3C2b4Ppd{BCe3OjeR?= M3XJT|AvOSEQvHevcWw> NE\ufJAxNTJ2IHi= M{nBWolv\HWlZYOgZZBweHSxc3nzJI9nKEOxbH:gNlA2KGOnbHzzJIlvKHO3c4DlcpNqd25iY4XseJVz\XN? M33iclI{QTd|OUm2
Colo 205 Mn\TSpVv[3Srb36gRZN{[Xl? M{fuV|AvODF3IN88[{9uVA>? M13iVlI1KGh? MlTlbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDFVkB{fHKnc4OtdoVt[XSnZDDn[Y5mew>? MV:yN|k4Ozl7Nh?=
Colo 205 NGm0WoZHfW6ldHnvckBCe3OjeR?= MlHMNE4xOTVizsznM41N MlyyNlQhcA>? MnOzbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVJM> M3q4OFI{QTd|OUm2
IBRS2 Mk\YSpVv[3Srb36gRZN{[Xl? NWjofHVEPSEQvHevcYw> NXXPcGhxOC53IHi= MYHEUXNQ M{TGdIRqe3K3cITzJJRp\SCHUlfJR{BidmRiR3;s[4nDqA>? MkTQNlM6PjN3M{S=
IBRS2 MXTGeY5kfGmxbjDBd5NigQ>? NWHQUHVIPSEQvHevcYw> MWewMlUhcA>? M{\zcGROW09? M3nMe4VvcGGwY3XzJGZOTFZiaX7m[YN1cW:w MWCyN|k3OzV|NB?=
HeLa MkXOSpVv[3Srb36gRZN{[Xl? MlvDNkDPxE1? NHL5WoQzKGkEoB?= MVHheJRmdnWjdHXzJJRp\SCWTl[tbY5lfWOnZDDz[YNz\XSrb36gc4YhUUxvMUW= NGjJdYMzOzl3MEi5Ni=>
HFS  NIrLNmlHfW6ldHnvckBCe3OjeR?= M2S0e|AuOSEQvHevcYw> Ml3ENlQhcA>? NFvpfWRIVFSSIHX4dJJme3Orb36gdoVi[2inczDhJJBt[XSnYYWgZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODFiwsXnM41t NYfuSHlIOjN6OUS2N|M>
HFS  Mn;WSpVv[3Srb36gRZN{[Xl? MnHPNE4xOSEEtXevcYw> MWKyOEBp NUe0PI1YcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGeueXPvd5BpcW6pb3zpdIllKHO7boToZZNmKGenbnXzJIF1KDZiaB?= MUKyN|g6PDZ|Mx?=
OVCAR-3 MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK3NgKBmzF3wrFOwG3DqA>? NImxOXczPMLiaB?= NWLpVHlLcW6mdXPld{BiKGyxc4Ogc4Yh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSuedMg NWnKcXFOOjN6Mk[5OlQ>
OVCAR-3 MlmzSpVv[3Srb36gRZN{[Xl? MWqx5qCUOTYEoN88UeKh NYL1WZFJOjUEoHi= NIO0OYxqdmS3Y3XzJI52[2ynYYKg[IFu[Wen M3rubVI{QDJ4OU[0
OVCAR-3 MWTBdI9xfG:|aYOgRZN{[Xl? NELFWo8yNTFywrFOwG0> NUeySZlsPCCq M4P6N4lv\HWlZYOgeIhmKGGldHn2ZZRqd25ib3[gZZBweHSxc3nzMZJmdGG2ZXSgdJJwfGWrboO= NWD4TnVZOjN6Mk[5OlQ>
OVCAR-3 MWXBdI9xfG:|aYOgRZN{[Xl? NVG3VZY1OTEEoN88US=> MoDJNlTDqGh? MVjpcoR2[2W|IHHjeIl3[XSrb36gc4Yh[2G|cHHz[ZM> MWOyN|gzPjl4NB?=
OVCAR-3 NX7wVFJMTnWwY4Tpc44hSXO|YYm= M1jvblHjiJNzMNMg{txO NV\id|RZOjUEoHi= NHvwO|lqdmS3Y3XzJIRqe3K3cITpc44hd2ZidHjlJI1qfG:laH;u[JJq[WxidILhcpNu\W2kcnHu[UBxd3SnboTpZYw> NXixfIdNOjN6Mk[5OlQ>
OVCAR-3 M1rSbmZ2dmO2aX;uJGF{e2G7 NFX1RXIy6oDVMUFCpO69VQ>? MVqyOOKhcA>? MWnpcoR2[2W|IH\vdo1ifGmxbjDv[kBz\WGldHn2[UBwgHmpZX6gd5Bm[2mncx?= MU[yN|gzPjl4NB?=
OVCAR-3 M2\1fGZ2dmO2aX;uJGF{e2G7 NEjhO4oy6oDVMUFCpO69VQ>? MmXyNlTDqGh? M1zqZolvcGmkaYTzJINmdGxiYXTo[ZNqd25iYX7kJI1q\3KjdHnvci=> M17r[FI{QDJ4OU[0
MKN45 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn70TWM2ODxyLkCwNUDPxGdxbXy= M3TJRVI{Pzl|M{Sy
LOVO Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O5dWlEPTB;MD6xNkDPxGdxbXy= MV[yN|c6OzN2Mh?=
A549 NHrTOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\PeWFWUUN3ME2wMlA1KM7:Zz;tcC=> M3rjNlI{Pzl|M{Sy
MDA-MB-435 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrreo5MUUN3MEywMlAxOSEQvHevcYw> MXGyN|c6OzN2Mh?=
HepG2 M3:xdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjUTWM2ODxyLkCwNUDPxGdxbXy= NFnWNWEzOzd7M{O0Ni=>
HL-60 NHzwdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRDBwMECxJO69\y:vbB?= MWiyN|c6OzN2Mh?=

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID